The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis’s Aimovig (erenumab) was the first to launch in May 2018, giving it a four-month head start over Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab). This U.S. launch-tracking series—DRG’s companion to our three-wave Aimovig series—will assess Ajovy and Emgality’s uptake and performance through the first year. We will also examine how Ajovy, Emgality, and Aimovig compare on various attributes and assess how physician adoption, opinion, and expectations shift as they gain more experience with each of these novel therapies.
Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.
Markets covered: United States.
Primary research: Survey of 75 U.S. neurologists for each wave.
Key metrics included: